The Canadian Diabetes Association provides clinical guidelines for the pharmacologic management of type 2 diabetes. The guidelines emphasize individualized treatment based on the patient's glycemic control, comorbidities, and lifestyle. If glycemic targets are not achieved within 2-3 months of lifestyle management, antihyperglycemic pharmacotherapy should be initiated. Timely adjustments and additions of agents are needed to achieve target HbA1c levels within 3-6 months. Metformin is recommended as the first-line therapy due to its effectiveness, safety, and minimal risk of hypoglycemia and weight gain. If metformin is insufficient, other agents should be added based on factors such as hypoglycemia risk, effectiveness, and weight impact. Combination therapy with two agents, one of which may be insulin, is considered for severe hyperglycemia (HbA1c ≥ 8.5%). Insulin is recommended for symptomatic patients with high HbA1c and blood glucose levels. The guidelines also address hypoglycemia, emphasizing the need for prevention, recognition, and treatment. They recommend using long-acting insulin analogs to reduce nocturnal hypoglycemia and rapid-acting analogs for better glycemic control. The guidelines also mention the importance of considering the patient's preferences, renal function, and other factors when selecting agents. The recommendations are based on evidence from clinical trials and meta-analyses, with a focus on achieving glycemic targets while minimizing complications. The guidelines also highlight the importance of lifestyle modification and regular monitoring of glycemic control and complications.The Canadian Diabetes Association provides clinical guidelines for the pharmacologic management of type 2 diabetes. The guidelines emphasize individualized treatment based on the patient's glycemic control, comorbidities, and lifestyle. If glycemic targets are not achieved within 2-3 months of lifestyle management, antihyperglycemic pharmacotherapy should be initiated. Timely adjustments and additions of agents are needed to achieve target HbA1c levels within 3-6 months. Metformin is recommended as the first-line therapy due to its effectiveness, safety, and minimal risk of hypoglycemia and weight gain. If metformin is insufficient, other agents should be added based on factors such as hypoglycemia risk, effectiveness, and weight impact. Combination therapy with two agents, one of which may be insulin, is considered for severe hyperglycemia (HbA1c ≥ 8.5%). Insulin is recommended for symptomatic patients with high HbA1c and blood glucose levels. The guidelines also address hypoglycemia, emphasizing the need for prevention, recognition, and treatment. They recommend using long-acting insulin analogs to reduce nocturnal hypoglycemia and rapid-acting analogs for better glycemic control. The guidelines also mention the importance of considering the patient's preferences, renal function, and other factors when selecting agents. The recommendations are based on evidence from clinical trials and meta-analyses, with a focus on achieving glycemic targets while minimizing complications. The guidelines also highlight the importance of lifestyle modification and regular monitoring of glycemic control and complications.